Danish trial demonstrates benefits of dual-chamber pacing in treating sick sinus syndrome

Aug 31, 2010

DANPACE, a Danish multicentre randomised trial comparing single lead atrial and dual chamber pacing in patients with sick sinus syndrome, concludes that dual chamber pacing, which was associated with lower rates of atrial fibrillation and re-operation, "should be the preferred pacing mode".

Behind the conclusion lies a 20-site study of 1415 subjects with sick sinus syndrome (a variety of arrhythmias caused by a malfunction of the sinus node, the heart's principal pacemaker) referred for their first pacemaker implantation. Pacemakers are routinely used to treat patients suffering from sick sinus syndrome.

The patients were randomised equally to single-lead atrial or dual-chamber pacemakers* and their progress followed for a mean of 6.4 years, producing over 7000 operational years of evidence. Results showed that all-cause were similar in both groups, 29.6% in the single-lead atrial pacemaker group and 27.3% in the dual chamber group. However, the prevalence of paroxysmal atrial fibrillation was lower in the dual chamber group than in the single-lead group (HR 0.79, p=0.024), with significantly fewer dual chamber patients requiring pacemaker re-operation during follow-up (HR 0.50, p<0.001).

Summarising the outcome, principal investigator Dr Jens Cosedis Nielsen from the Department of Cardiology, Skejby Hospital in Aarhus, Denmark, said: “The results showed that, when compared with dual-chamber pacing, single-lead atrial pacing was associated with a 27% increase in the risk of developing atrial fibrillation and a doubling of the risk of having to undergo a pacemaker re-operation.

“In prior trials, ventricular stimulation has been found to increase the incidences of atrial fibrillation and heart failure. However, in this patient group we demonstrated for the first time that dual-chamber pacing actually decreases atrial fibrillation and has no influence on the incidence of when compared with single-lead atrial pacing without ventricular stimulation.”

Explore further: Animated tips on how you should and shouldn't approach the visually impaired

Related Stories

Osteoporosis drug may be associated with irregular heartbeat

Apr 28, 2008

Alendronate, a medication used to prevent fractures in women with osteoporosis, may be associated with an increased risk of atrial fibrillation, a type of abnormal heart rhythm, according to a report in the April 28 issue ...

Recommended for you

Drug and device firms paid $6.5B to care providers

Jun 30, 2015

From research dollars to free lunches and junkets, drug and medical device companies paid doctors and leading hospitals nearly $6.5 billion last year, according to government data posted Tuesday.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.